CD3+Tbet+ T cells were enriched in TLO from evanescent prostate carcinoma patients, as shown by the significant increase in the ratio between Tbet+ and Foxp3+ T cells (6.47 ± 1.76), relative to PIN (1.1 ± 0.7, p = 0.0006), intermediate (2.25 ± 0.76, p < 0.0001), and advanced prostate carcinoma patients (1.63 ± 0.67, p < 0.0001) (Figure 8G). Here, FOXP3 is linked to prostate carcinoma.